http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2468799-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7929fac7d767900c0fb80a9a76e09ec6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 |
| filingDate | 2011-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a25320c3edde2462cc32cedd1f409380 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13ceb4df9f5e35745bd70f1033d4c317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3436f5acc63b7893b6dce1a8a21e7209 |
| publicationDate | 2012-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2468799-C1 |
| titleOfInvention | Method of relieving alcohol abstinence syndrome by blockade of benzodiazepine receptors |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely addictology, and deals with relief of alcohol abstinence syndrome by blockade of benzodiazepine receptors. For this purpose anexate is introduced intravenously. Introduction is performed twice in strict succession through fixed 3 hours in dose 0.5 mg, reaching complete reduction of main clinical manifestations of alcohol abstinence syndrome. Duration of each introduction is 3-5 minutes. n EFFECT: method ensures increase of treatment efficiency and reduction of terms of relieving psychoneurologic and somato-vegetative manifestations of alcohol abstinence. n 1 ex |
| priorityDate | 2011-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.